Pharma & Biotech - Page 2

Novo Nordisk has reported a significant phase 3 trial result for Wegovy in younger children, with two in five participants no longer classified as having obesity after 68 weeks of treatment. The

Gregg Gorniak, vice president of manufacturer operations and data services and secure supply chain lead at Cencora, argues that DSCSA compliance investments only create value when trading partners agree on what “value”

Sandoz is positioning itself for long-term growth by making significant investments in its biosimilar capabilities over the coming years. The Swiss generics and biosimilars giant sees a major commercial opportunity on the

Pharmaceutical cargo has historically represented the gold standard of supply chain security, with the industry investing heavily in layered protections and advanced technology. The sector has long recognised its lower risk tolerance

Amgen has announced landmark results from its Phase 3 DeLLphi-305 study, marking a significant breakthrough in the treatment of small cell lung cancer. The trial met its primary endpoint at a pre-specified

Ameer Ali, senior director of manufacturer operations and data services at Cencora, is urging trading partners to begin preparing their systems for the NDC-12 transition long before the rule takes effect. Ali

Roche has once again swept all four versions of a major neurology corporate reputation ranking compiled by patient advocacy research organisation PatientView. The Swiss pharmaceutical giant secured top position among companies that

AstraZeneca (AZN) has launched a new marketing campaign for its Breztri inhaler, targeting asthma patients for the first time after years of COPD-focused advertising. The campaign marks a significant shift, as Breztri

Major pharmaceutical companies including Roche, GSK, and Novartis are at the centre of a flurry of deal-making and drug pricing agreements reshaping the industry landscape. GSK moved first among the late movers

UCB’s Bimzelx emerged as a notable newcomer in August’s pharmaceutical television advertising rankings, claiming ninth place among the top spending drug brands. The psoriasis and psoriatic arthritis medication displaced Intra-Cellular Therapies’ Caplyta